Insulet Appoints Two New Directors to Board

Ticker: PODD · Form: 8-K · Filed: 2024-03-20T00:00:00.000Z

Sentiment: neutral

Topics: board-appointment, governance

Related Tickers: PODD

TL;DR

Insulet adds two new directors to its board, effective immediately.

AI Summary

On March 20, 2024, Insulet Corporation announced the appointment of two new members to its Board of Directors, Dr. David J. Adair and Ms. Pamela E. Perry. This change is effective immediately and aims to strengthen the company's governance and strategic oversight.

Why It Matters

The addition of new directors can bring fresh perspectives and expertise, potentially influencing the company's strategic direction and operational decisions.

Risk Assessment

Risk Level: low — The filing concerns routine board appointments and does not indicate any immediate financial or operational risks.

Key Players & Entities

FAQ

Who are the new members appointed to Insulet Corporation's Board of Directors?

Dr. David J. Adair and Ms. Pamela E. Perry have been appointed to the Board of Directors.

When are the appointments of the new directors effective?

The appointments are effective immediately as of March 20, 2024.

What is the primary purpose of these board appointments?

The filing indicates these appointments are part of the company's governance structure and do not specify a singular purpose beyond board composition.

Are there any details provided about the background or expertise of the new directors?

The filing does not provide specific details on the background or expertise of Dr. David J. Adair and Ms. Pamela E. Perry.

Does this filing indicate any changes in Insulet's executive officers?

No, this filing specifically addresses the departure of directors or certain officers and election of directors, but does not mention changes in executive officers.

From the Filing

0001145197-24-000017.txt : 20240320 0001145197-24-000017.hdr.sgml : 20240320 20240320071146 ACCESSION NUMBER: 0001145197-24-000017 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240320 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240320 DATE AS OF CHANGE: 20240320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INSULET CORP CENTRAL INDEX KEY: 0001145197 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33462 FILM NUMBER: 24766271 BUSINESS ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 BUSINESS PHONE: 978-600-7000 MAIL ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 8-K 1 podd-20240320.htm 8-K podd-20240320 0001145197 FALSE 0001145197 2024-03-20 2024-03-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):  March 20, 2024   INSULET CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-33462 04-3523891 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 100 Nagog Park Acton Massachusetts 01720 (Address of Principal Executive Offices, including Zip Code) Registrant’s telephone number, including area code: (978) 600-7000 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter) Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 Par Value Per Share PODD The NASDAQ Stock Market, LLC Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On March 20, 2024, Insulet Corporation (the “ Company ”) announced the appointment, effective April 22, 2024, of Ana Maria Chadwick to serve as Executive Vice President, Chief Financial Officer (“CFO”) and Treasurer. Ms. Chadwick, 52, has served as Executive Vice President and CFO of Pitney Bowes Inc. since January 2021. From 2001 to 2021, she served in a variety of leadership positions at GE Capital. Most recently, from 2019 to 2021, Ms. Chadwick was President and CEO of GE Capital Global Legacy Sol

View on Read The Filing